Another kinase inhibitor shows only “modest” activity in men with mCRPC

A relatively small Phase II trial, carried out in France and Germany, has suggested that a new kinase inhibitor called nintedanib has only “modest” activity in the treatment of post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Sweeney et al. present results of CHAARTED trial at ASCO

So the data from the CHAARTED trial will be presented this afternoon at the ASCO meeting. This is the one really major and positive study result related to prostate cancer that we knew was coming at this meeting. … READ MORE …

Sunday morning’s news from the ASCO annual meeting

We commented earlier on several of the prostate cancer presentations given this morning at the American Society for Clinical Oncology (ASCO) meeting — see here and here. However, there was another important paper presented this morning. … READ MORE …

What’s being presented at ASCO this year: I

So here are some links to some initial key papers to be presented at ASCO this year. These four papers all address important issues affecting the treatment of metastatic and later stages of prostate cancer. … READ MORE …

Decision about enzalutamide in chemo-naive mCRPC

According to a joint media release, issued yesterday by Medivation and Astellas, the U.S. Food & Drug Administration (FDA) has granted a priority review for the supplementary New Drug Application (sNDA) for the use of enzalutamide in the treatment of chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Custirsen does NOT significantly extend survival in men with mCRPC

OncoGenex and Teva stated earlier today that the addition of custirsen (OGX-011) to docetaxel + prednisone did not demonstrate any significant effect on the overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

OncoGenex gets addditional “fast track” designation for custirsen

According to a media release from OncoGenex, the U.S. Food & Drug Administration has granted a “fast track” designation to the evaluation of data from the so-called AFFINITY trial of custiren + carbazitaxel + prednisone as a second-line treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Palliative (and non-palliative) radiation therapy in late-stage prostate cancer today

The role of radiation therapy in the management of men with advanced (i.e., metastatic and castration-resistant) forms of prostate cancer has been evolving over the past 5 years or so. … READ MORE …

Is AR-V7-positive status a contraindication to enzalutamide therapy?

According to a media release issued by the American Association for Cancer Research (AACR), it may be possible to identify some men with advanced prostate cancer who are highly likely to be resistant to treatment with enzalutamide. … READ MORE …

The potential of metformin in prostate cancer treatment: an update

We have previously commented (more than once) on the perception that metformin may have some value in the management of prostate cancer. A recently reported (albeit small), prospective Swiss study, has added to our knowledge in this regard. … READ MORE …

COMET-1 trial does not show survival benefit … yet

Some in the investment community (and probably many in Exelixis itself) had been hoping that an interim analysis of an ongoing Phase III trial of cabozantinib (Cometriq) in the treatment of late-stage prostate cancer would show a positive outcome and allow the trial to be stopped early. … READ MORE …

AB Science initiates Phase III trial of masitinib in mCRPC, but …

A French company called AB Science has initiated a Phase III clinical trial of masitinib (yet another tyrosine kinase inhibitor) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

To prednisone or not to prednisone? Is that the question?

The past couple of years have seen a resurgence of academic (and clinical) interest in the value of the corticosteroid prednisone in combination with other drugs in the treatment of men with advanced forms of prostate cancer. … READ MORE …

Results of Phase III trial of custirsen (OGX-011) in mCRPC coming soon

According to a media release issued early this morning by OncoGenex Pharmaceuticals, the Phase III SYNERGY trial of custirsen (originally known as OGX-011) has reached its pre-specified endpoint in terms of the number of events required for final analysis of the trial data. … READ MORE …

Evaluating the risks and benefits of prednisone

Over the past 20 years or so, the oral corticosteroid prednisone has been used regularly in combination with drugs like mitoxantrone, docetaxel, cabazitaxel, ketoconazole, and abiraterone acetate in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers